Natreon has been granted a U.S. Patent (US 10,500,240) on Terminalia chebula.
Photo © Shutterstock.com/jovan vitanovski
Natreon (New Brunswick, NJ) has been granted a U.S. Patent (US 10,500,240) on Terminalia chebula. The primary claim in the patent is “a method of treating osteoarthritis in a mammal, comprising administering to a mammal in need thereof a therapeutically effective amount of a composition comprising a Terminalia chebula extract comprising a hydrolyzable tannoid blend, said blend comprising about 8-25% by weight chebulagic acid based on the total weight of the extract and about 15-30% by weight chebulinic acid based on the total weight of the extract.”
The secondary claim in this patent is “a method of reducing pain and inflammation in an individual with osteoarthritis in need thereof, comprising orally administering to the individual in need thereof a therapeutically effective amount of a composition comprising a Terminalia chebula extract comprising a hydrolyzable tannoid blend, said blend comprising about 8-25% by weight chebulagic acid based on the total weight of the extract and about 15-30% by weight chebulinic acid based on the total weight of the extract.”
This latest patent brings Natreon’s latest patent portfolio to 24 active patents, as well as 40 published clinical trial.
Judge denies CRN’s motion for preliminary injunction but its lawsuit against NY state will proceed
April 23rd 2024The judge in CRN's lawsuit against NY state's law banning the sale of weight management and muscle building supplements to minors has denied its motion for a preliminary injunction, but determined that CRN has standing to sue on behalf of its members.
Arla Foods to acquired whey nutrition business from Volac International
April 22nd 2024Arla Foods Ingredients has reached an agreement to acquire Volac’s Whey Nutrition business through a purchase of shares in Volac Whey Nutrition Holdings Limited and its subsidiary, Volac Whey Nutrition Limited and Volac Renewable Energy Limited.